EDITAS MEDICINE, INC. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax
EDITAS MEDICINE, INC. (EDIT) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax of $6.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $6.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $0.00.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2026-06-30 | $6.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $5.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $5.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $21.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $31.00K 10-Q · filed 2024-11-04 |
| 2024-06-30 | $460.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $392.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $413.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | $1.47M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $2.29M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $2.35M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $3.62M 10-K · filed 2024-02-28 |
| 2022-09-30 | $4.30M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $3.40M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $2.52M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $495.00K 10-K · filed 2023-02-22 |
| 2021-09-30 | $74.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $84.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $88.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $64.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $69.00K 10-Q · filed 2020-11-06 |
| 2018-12-31 | $29.00K 10-K · filed 2019-03-01 |
| 2018-09-30 | $82.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $4.00K 10-Q · filed 2018-08-07 |
| 2018-03-31 | $53.00K 10-Q · filed 2018-05-04 |
| 2017-12-31 | $76.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |